
From Oncology Nurse to Care Partner: Lessons From a Couple Facing NMIBC
JoAnne Page, RN, a breast cancer survivor, shares what oncology nurses can do for care partners of patients with bladder cancer.
When Ray Page's non-muscle invasive bladder cancer (NMIBC) recurred after first-line therapy, his wife, JoAnne Page, RN, brought 2 perspectives to his care: that of a nurse with an oncology background and that of a breast cancer survivor.
For National Family Caregivers Month and Bladder Health Month, the couple told Oncology Nursing News that clinical knowledge helped, but that care partners still need nurses to check on them.
"Having the clinical background, it kind of gives you an idea of what to expect, what the future could have been," JoAnne said. "And with that being said, it's not always positive." She described the emotional part of being a nurse and the emotional part of being a wife and caregiver as "very different."
What happened when first-line therapy failed?
Ray was diagnosed with NMIBC in 2025 and received bacillus Calmette-Guérin (BCG), which fails in up to 40% of patients with NMIBC.3 Tumors returned after a partial cystectomy, and bladder removal was on the table. Ray said the visits became harder for the nurses as results kept coming back positive. "It was systematically BCG, scope, bad news," he said. "After a few of those, it was like, 'Well, what do we say to this guy?'"
In January 2026, Ray began gemcitabine intravesical system (Inlexzo), which the FDA approved on September 9, 2025, for adults with BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.1 In cohort 2 of the phase 2b SunRISe-1 trial (NCT04640623), 82% of 83 patients had a complete response (95% CI, 72%-90%), and 51% of responders maintained a response for at least 12 months.1 Each system dwells in the bladder for 3 weeks; insertions occur every 3 weeks for up to 6 months, then every 12 weeks for up to 18 months.1
The most common adverse reactions included urinary frequency (48%), urinary tract infection (44%), dysuria (42%), and micturition urgency (34%), and 41% of patients had a dosage interruption due to an adverse reaction.2 Prior Oncology Nursing News coverage outlined
How did the care team handle a first-in-practice treatment?
Ray said his was the first insertion at his practice. "There were 2 nurses from J&J that were there to help him understand and go through the process," he said.
How can nurses support care partners?
JoAnne said advocacy starts with presence. "My thought is for advocacy is being with them for the appointments, talking and being the other set of ears to hear what's being said," she said. After working in home care, she added, "I was amazed at how much people do not recall."
Her advice for nurses is simple. "Sometimes it's just as simple as, 'How are you doing?'" she said. In her own calls with patients, she said, "I always, always tell the caregivers, 'You're the one I worry about.'" Additional ONN coverage offers
Ray reported no new tumors since starting treatment. "It's strengthened us. It's given us a lot of hope," he said.
What are the key takeaways for oncology nurses?
- Ask the care partner directly. A question about how they are doing can open the door to support.
- Invite a second set of ears. Patients may recall little of what is said during visits.
- Prepare for first-in-practice therapies. Coordinate training and patient education before the first insertion.
- Monitor urinary symptoms. Urinary frequency, infection, dysuria, and urgency were common with gemcitabine intravesical system.2
References
1. FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer. FDA. September 9, 2025. Accessed November 4, 2026.
2. Inlexzo (gemcitabine intravesical system). Prescribing information. Janssen Biotech, Inc; 2025. Accessed November 4, 2026.
3. Steinberg RL, Thomas LJ, O'Donnell MA. Bacillus Calmette-Guérin (BCG) treatment failures in non-muscle invasive bladder cancer: what truly constitutes unresponsive disease. Bladder Cancer. 2015;1(2):105-116. doi:10.3233/BLC-150015
4. Hoyt B. What should nurses know: gemcitabine intravesical system's approval. Oncology Nursing News. September 16, 2025. Accessed November 4, 2026.
5. Caring for the caregiver: practical tips for oncology nurses. Oncology Nursing News. Accessed November 4, 2026.
Related to this article








